Heterogenous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 4, 1998, Pages 1368-1375

  Renner, Ulrich ^a   Arzberger, Thomas ^b   Pagotto, Uberto ^a   Leimgruber, Susanne ^b   Uhl, Eberhard ^c   Müller, Adolf ^c   Lange, Manfred ^d   Weindl, Adolf ^b   Stalla, Günter K ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Clinic of Mannheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; LUTEINIZING HORMONE; MESSENGER RNA; PROLACTIN; RECEPTOR SUBTYPE;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; IN SITU HYBRIDIZATION; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; ADENOMA; BIOSYNTHESIS; CASE CONTROL STUDY; CYTOLOGY; GENETICS; HYPOPHYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; BROMOCRIPTINE; CASE-CONTROL STUDIES; DOPAMINE AGONISTS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PITUITARY GLAND; PITUITARY NEOPLASMS; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0031594107     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.4.1368     Document Type: Article

References (44)

1. Civelli O, Bunzow JR, Grandy DK. 1993 Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol. 32:281-307.
2. Gingrich JA, Caron MG. 1993 Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci. 16:299-321.
3. Dal Toso R, Sommer B, Ewert M, et al. 1989 The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J. 8:4025-4034.
4. 2 dopamine receptor isoforms. Nature. 342:923-926.
5. 2 dopamine receptors produced by alternative RNA splicing. Nature. 342:926-929.
6. 2 dopamine receptor isoforms. FEBS Lett. 278:239-243.
7. Lamberts SWJ, MacLeod RM. 1990 Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev. 70:279-318.
8. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992 Dopamine agonists and pituitary shrinkage. Endocr Rev. 13:220-240.
9. Scillatini A, Dicembrino F, Di Fazio P, et al. 1995 In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab. 80:2523-2525.
10. Pellegrini I, Rasolonjanahary R, Gunz G, et al. 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 69:500-509.
11. Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W. 1995 Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. J Neurosurg. 82:886-890.
12. Autelitano DJ, van den Buse M. 1995 Altered expression of dopamine D2 receptor mRNA splice variants in brain and pituitary of spontaneously hypertensive rats. Neurosci Lett. 195:1-4.
13. Bevan JS, Burke CW. 1986 Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf). 25:561-572.
14. Muhr C, Bergstrom M, Lundberg PO, Langstrom B. 1991 PET imaging of pituitary adenomas. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A, eds. Pituitary adenomas: new trends in basic and clinical research. New York: Elsevier Science; 237-244.
15. Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N. 1995 Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas. Clin Endocrinol (Oxf). 42:593-599.
16. Colao A, Ferone D, Marzullo P, et al. 1997 Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 82:518-523.
17. Mercado-Asis LB, Yanovski JA, Tracer HL, Chik CL, Cutler GB. 1997 Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome. J Clin Endocrinol Metab. 82:514-517.
18. Halse J, Harris AG, Kvistborg A, et al. 1990 A randomized study of SMS 201-995 vs. bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab. 70:1254-1261.
19. Liuzzi A, Dallabonzana D, Oppizzi G, et al. 1991 Is there a real medical treatment for "non secreting" pituitary adenomas? In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A, eds. Pituitary adenomas: new trends in basic and clinical research. New York: Elsevier Science; 383-390.
20. Sadoul J-L, Thyss A, Freychet P. 1992 Invasive mixed growth hormone/ prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. Acta Endocrinol (Copenh). 126:179-183.
21. Renner U, Mojto J, Lange M, Müller OA, von Werder K, Stalla GK. 1994 Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol. 130:80-91.
22. Grossman A, Ross R, Charlesworth M, et al. 1985 The effect of dopamine agonist therapy on large functionless pituitary tumours. Clin Endocrinol (Oxf). 22:679-686.
23. Friedman E, Adams EF, Höög A, et al. 1994 Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab. 78:568-574.
24. Pagotto U, Arzberger T, Hopfner U, et al. 1995 Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J Clin Invest. 96:2017-2025.
25. Arzberger T, Krampfl K, Leimgruber S, Weindl A. 1997 Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. J Neuropathol Exp Neurol. 56:440-454.
26. Renner U, Newton CJ, Pagotto U, Sauer J, Arzt E, Stalla GK. 1995 Involvement of interleukin-1 and interleukin-1 receptor antagonist in rat pituitary cell growth regulation. Endocrinology. 136:3186-3193.
27. Godfrey K. 1986 Comparing the means of several groups. In: Bailar JC, Mosteller F, eds. Medical uses of statistics. Waltham, MA: NEJM Books; 205-235.
28. Tapar K, Kovacs K, Laws ER, Muller PJ. 1993 Pituitary adenomas: current concepts in classification, histopathology, and molecular biology. Endocrinologist. 3:39-57.
29. 2 receptors using solution hybridization. Neurochem Int. 20[Suppl]:189S-195S.
30. 444, in two types of lactotroph each characterised by their response to dopamine, and modification of expression by sex steroids. Endocrinology. 129:1101-1103.
31. Kwekkeboom DJ, Hofland LJ, Van Koetsveld PM, Singh R, Van den Berge JH, Lamberts SWJ. 1990 Bromocriptine increasingly suppresses the in vitro gonadotropin and a-subunit release from pituitary adenomas during long-term culture. J Clin Endocrinol Metab. 71:718-724.
32. 2 dopamine receptor messenger RNA in the rat brain. Neuroscience. 69:159-166.
33. Judd AM, Login IS, Kovacs K, et al. 1988 Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine. Endocrinology. 123:2341-2350.
34. 2L receptor coupled to native transduction mechanisms. J Mol Endocrinol. 14:375-389.
35. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 60:314-322.
36. B subtypes in a heterologous cell line. Mol Endocrinol. 6:920-926.
37. Vallar L, Muca C, Magni M, et al. 1990 Different coupling of dopaminergic D2 receptors expressed in different cell types. J Biol Chem. 265:10320-10326.
38. Montmayeur J-P, Borrelli E. 1991 Transcription mediated by a cAMP-responsive promoter element is reduced upon activation of dopamine D2 receptors. Proc Natl Acad Sci USA. 88:3135-3139.
39. 2+ currents in rat anterior pituitary cells. Neuron. 8:455-463.
40. Montmayeur J-P, Guiramand J, Borrelli E. 1993 Preferential coupling between dopamine D2 receptors and G-proteins. Mol Endocrinol. 7:161-170.
41. 2A to regulate prolactin promoter activity. Mol Cell Endocrinol. 111:129-137.
42. sα, in dopamine and thyrotropin-releasing hormone signal transducrion: evidence for competition and commonality. J Endocrinol. 148:447-455.
43. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A. 1996 Alteration of Ga subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol. 8:737-746.
44. Lania A, Reza-Elahi F, Gil-del-Alamo P, Saccomanno K, Mantovani S, Spada A. 1995 Abnormal transduction of dopamine signal in human nonfunctioning pituitary adenomas. J Endocrinol Invest. 18:265-270.